Longevity Medical Institute Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers
Summary: Physicians and scientists from Longevity Medical Institute® (Los Cabos, Baja California Sur, Mexico) announced on March 11, 2026 the publication of a peer-reviewed systematic review and meta-analysis in the Journal of Surgery and Medical Case Reports (DOI: 10.64142/jsmcr.3.1.59) titled “Allogeneic Mesenchymal Stromal Cell-Based Therapies for Diabetic Foot Ulcers: Systematic Review and Meta-Analysis of Controlled Topical and Local Delivery Trials.” The research team, led by Kirk Sanford, DC (Longevity Medical Institute founder), included Félix Porras, MD; Fergie Martínez, MD, MSc; Hugo Ramos, MD; Janine Zamitiz, MD, MSc; Carlos Green, MSc; and Edward Ramsay, MSc. The study reviewed and meta-analysed controlled clinical studies examining allogeneic mesenchymal stem cell (MSC) therapies delivered by topical application or local injection in patients with diabetic foot ulcers — a population for which conventional treatments frequently fail due to diabetes-related impairments in circulation, immune function, and tissue repair signalling. The analysis found that MSC therapies were associated with improved wound closure rates and greater reductions in ulcer size compared with standard wound care alone. Proposed biological mechanisms include immune modulation, promotion of angiogenesis, and activation of regenerative signalling pathways involved in tissue repair. The publication is notable given Mexico’s large stem cell clinic sector, where relatively little peer-reviewed research originates domestically. Longevity Medical Institute recently opened a federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos under COFEPRIS, Mexico’s national regulatory authority, and operates an integrated medical campus offering AI-enhanced full-body MRI imaging, cardiovascular assessment, a clinical laboratory measuring over 120 biomarkers, and surgical services. Readers should note that Longevity Medical Institute is a for-profit regenerative medicine center and this publication should be evaluated alongside the full study methodology and independent literature.
Key Highlights:
- Systematic review and meta-analysis of controlled trials: allogeneic MSC therapies (topical and local injection delivery) for DFUs; Journal of Surgery and Medical Case Reports; DOI: 10.64142/jsmcr.3.1.59; March 2026
- Key finding: MSC therapies associated with improved wound closure rates and greater ulcer size reduction versus standard care alone across controlled clinical studies
- Proposed mechanisms: MSC-mediated immune modulation, angiogenesis promotion, and activation of regenerative tissue repair signalling — addressing the chronic inflammatory and hypoperfused DFU microenvironment
- Institutional context: COFEPRIS-licensed biotechnology laboratory in Los Cabos; integrated medical campus with AI-enhanced MRI, cardiovascular assessment, biomarker laboratory, and surgical services
- Research team: Kirk Sanford, DC (lead); Félix Porras, MD (Medical Director); Fergie Martínez, MD, MSc; Hugo Ramos, MD; Janine Zamitiz, MD, MSc; Carlos Green, MSc; Edward Ramsay, MSc
- Context note: Longevity Medical Institute is a for-profit stem cell and regenerative medicine center; readers are encouraged to review the full publication methodology and evaluate the findings alongside independent systematic reviews in the MSC/DFU literature
Keywords: mesenchymal stem cell diabetic foot ulcer, stem cell therapy chronic wound, allogeneic MSC wound healing, regenerative medicine diabetic wound, DFU stem cell meta-analysis, wound closure stem cell therapy
Kirk Sanford Félix Porras Fergie Martínez Hugo Ramos Janine Zamitiz Carlos Green Edward Ramsay